Authors ’ Reply to Garattini and Freemantle: “Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition”
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research
More News: Economics | Health Management